GO:0050929 induction of negative chemotaxis: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0050929 (induction of negative chemotaxis) describes the initiation of directed cell movement away from a chemical gradient, a process critical for immune cell positioning, bacterial behavior, and developmental patterning [1,2,6].
• Key molecular players include chemokine receptors such as CCRL2 and CXCR2, which regulate leukocyte migration and can be induced by inflammatory signals [6,8].
• Pathogens like Epstein-Barr virus can hijack chemotaxis pathways, inducing aberrant B cell migration via FAK-dependent signaling.
• TRAIL promotes neutrophil chemotaxis through NFkB2 signaling in the tumor microenvironment, linking negative chemotaxis induction to cancer immune suppression.
• Bacterial systems, such as Myxococcus xanthus and gram-negative dormancy exit, provide tractable models for studying the induction of negative chemotaxis [4,7].
• CRISPR-based knockout, knock-in, and overexpression models are essential to dissect the causal roles of chemotaxis-related genes in health and disease [1,6].
Description
The Gene Ontology (GO) term GO:0050929, induction of negative chemotaxis, refers to any process that initiates the directed movement of a motile cell or organism towards a lower concentration of a specific chemical [1,6]. This biological process is fundamental for immune surveillance, where leukocytes must navigate complex chemokine gradients to reach sites of inflammation or to egress from tissues. Dysregulation of negative chemotaxis contributes to pathologies ranging from chronic inflammatory diseases to cancer metastasis, making it a critical area of biomedical research [2,3]. Understanding the molecular triggers that induce cells to move away from a chemical source is essential for developing therapies that modulate cell migration [6,8]. Recent studies have identified specific receptors and signaling cascades, such as CCRL2 and FAK-dependent pathways, that initiate negative chemotaxis in response to environmental cues [2,6]. This article synthesizes current knowledge on the induction of negative chemotaxis, highlighting key genes, experimental models, and research methods for studying this process.
induction of negative chemotaxis At A Glance
| GO ID | GO:0050929 |
|---|---|
| GO term | induction of negative chemotaxis |
| Ontology | biological_process |
| Synonym | none |
| Definition | Any process that initiates the directed movement of a motile cell or organism towards a lower concentration in a concentration gradient of a specific chemical. |
| Major function | Initiation of directed cell movement away from a chemical source, critical for immune cell trafficking, bacterial behavior, and developmental processes. |
| Related processes | Chemotaxis, negative chemotaxis, cell migration, leukocyte migration. |
| Key regulators | Chemokine receptors (e.g., CCRL2, CXCR2), FAK, NFkB2, and bacterial chemotaxis proteins. |
| Research relevance | Target for anti-inflammatory and anti-metastatic therapies; model for bacterial dormancy exit and host-pathogen interactions. |
What Is GO:0050929?
In our own words, induction of negative chemotaxis (GO:0050929) is the set of biological events that trigger a motile cell or organism to begin moving away from a higher concentration of a chemical substance toward a lower concentration. It is not the movement itself, but the initiation or induction of that directed migration in response to a chemical gradient [1,6].
Why Is induction of negative chemotaxis Important in Cell Biology?
Induction of negative chemotaxis is important because it governs how cells interpret and respond to chemical gradients to avoid harmful environments or to exit tissues during immune responses. In cancer, tumor cells can exploit negative chemotaxis to metastasize, and immune cells can be misdirected to promote tumor progression [2,3]. In infectious diseases, pathogens like Epstein-Barr virus manipulate chemotaxis pathways to spread within the host. Understanding the induction mechanisms provides opportunities for therapeutic intervention in inflammatory diseases, cancer, and bacterial infections [6,8].
• Regulates immune cell trafficking and positioning during inflammation and homeostasis.
• Contributes to cancer metastasis by guiding tumor cells away from primary sites.
• Modulates neutrophil recruitment and immune suppression in triple negative breast cancer.
• Influences bacterial exit from dormancy and developmental transitions [4,7].
• Provides targets for anti-inflammatory drugs, such as mirabebron reducing CXCR2 expression.
• Essential for host-pathogen interactions, including EBV-induced B cell migration.
• Involved in adipose tissue remodeling and myofibroblast regulation in obesity.
• Serves as a model for understanding gradient sensing and signal transduction [1,5].
• Links to primary atopic disorders through genomic sequencing of chemotaxis genes.
• Enables CRISPR-based functional studies of chemotaxis in health and disease [1,6].
What Happens During induction of negative chemotaxis?
Chemokine receptor activation
In simple terms: A cell detects a chemical signal through receptors on its surface, which triggers a response to move away.
The induction of negative chemotaxis begins when specific chemokine receptors, such as CCRL2 or CXCR2, bind to their ligands in the extracellular environment [6,8]. This binding activates intracellular signaling cascades that lead to cytoskeletal rearrangements and directed migration away from the chemical source. For example, CCRL2 regulates leukocyte migration by modulating chemokine availability and receptor signaling.
Intracellular signaling and FAK pathway
In simple terms: Inside the cell, a series of molecular switches are flipped to tell the cell to move away.
Upon receptor activation, focal adhesion kinase (FAK) and other signaling molecules are recruited to initiate downstream events. Epstein-Barr virus can induce aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways, demonstrating how pathogens hijack this induction process. This signaling leads to actin polymerization and myosin contraction, driving cell movement away from the gradient.
Transcriptional regulation of chemotaxis genes
In simple terms: The cell changes which genes are turned on or off to sustain movement away from the chemical.
Induction of negative chemotaxis often requires changes in gene expression. For instance, TRAIL induces cytokine production via the NFkB2 pathway, promoting neutrophil chemotaxis and immune suppression in triple negative breast cancer cells. This transcriptional reprogramming ensures that the cell maintains its migratory response.
Bacterial chemotaxis induction
In simple terms: Bacteria also sense chemicals and swim away, using a similar but simpler system.
In bacteria, induction of negative chemotaxis involves phosphoenolpyruvate:carbohydrate phosphotransferase systems (PTS) that modulate flagellar rotation. For example, in Myxococcus xanthus, beta-lactamase induction influences developmental transitions that require negative chemotaxis. Gram-negative cells exiting dormancy show defined temporal expression patterns that include chemotaxis-related genes.
Key Genes Involved in GO:0050929 induction of negative chemotaxis
The following genes and proteins are central to the induction of negative chemotaxis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CCRL2 | Atypical chemokine receptor that regulates leukocyte migration by scavenging chemokines | Target for modulating inflammation; studied in leukocyte trafficking |
| CXCR2 | Chemokine receptor mediating neutrophil recruitment | Reduced by mirabegron in obesity; potential target for anti-inflammatory therapy |
| FAK (PTK2) | Focal adhesion kinase involved in EBV-induced B cell migration | Key signaling node in pathogen-induced chemotaxis |
| NFkB2 | Transcription factor mediating TRAIL-induced cytokine production | Links chemotaxis to immune suppression in breast cancer |
| TRAIL (TNFSF10) | Cytokine that induces neutrophil chemotaxis via NFkB2 | Therapeutic target in triple negative breast cancer |
| PTS system components | Bacterial phosphotransferase system regulating chemotaxis | Model for bacterial signal transduction |
| Beta-lactamase | Enzyme influencing development in Myxococcus xanthus | Model for bacterial developmental chemotaxis |
| Dormancy exit regulators | Temporal expression patterns in gram-negative bacteria | Model for bacterial awakening and chemotaxis |
| CCR7 | Chemokine receptor involved in leukocyte migration | Studied in context of CCRL2 regulation |
| CXCL8 (IL-8) | Chemokine ligand for CXCR2 | Mediates neutrophil chemotaxis |
| Mirabegron target (ADRB3) | Beta-3 adrenergic receptor agonist reducing CXCR2 | Therapeutic modulation of chemotaxis in obesity |
| EBV proteins (e.g., LMP1) | Viral factors inducing FAK-dependent migration | Model for pathogen-induced chemotaxis |
| Atopic disorder genes | Genes identified by genomic sequencing in primary atopic disorders | Link chemotaxis to allergic diseases |
| Neutrophil chemotaxis effectors | Downstream signaling molecules in neutrophils | Targets for immune suppression in cancer |
| Bacterial flagellar motors | Rotary motors that drive chemotaxis | Model for directed movement |
| Myxococcus xanthus developmental genes | Genes coordinating development and chemotaxis | Model for bacterial multicellularity |
How Is induction of negative chemotaxis Regulated?
The induction of negative chemotaxis is regulated at multiple levels. Receptor availability and desensitization control the sensitivity of cells to chemokine gradients. For example, CCRL2 regulates leukocyte migration by acting as a scavenger receptor that modulates local chemokine concentrations. In obesity, mirabegron treatment reduces CXCR2 expression in adipose tissue, thereby altering chemotaxis induction. Transcriptional regulation via NFkB2 in response to TRAIL modulates neutrophil chemotaxis in cancer. Bacterial chemotaxis is regulated by the phosphorylation state of PTS components and flagellar motor switches. These regulatory mechanisms ensure that cells respond appropriately to changing chemical environments.
induction of negative chemotaxis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TRAIL | Triple negative breast cancer immune suppression | Knockout of TRAIL in cancer cell lines; neutrophil chemotaxis assays |
| CXCR2 | Obesity-associated adipose inflammation | CXCR2 knockout mice; mirabegron treatment |
| CCRL2 | Chronic inflammatory diseases | CCRL2 knockout mice; leukocyte migration assays |
| FAK | EBV-associated B cell malignancies | FAK knockout B cells; EBV infection models |
| PTS system | Bacterial infections and dormancy | PTS mutants in gram-negative bacteria; chemotaxis assays |
Cancer and immune suppression
Induction of negative chemotaxis plays a dual role in cancer. Tumor cells can exploit chemotaxis to metastasize, while immune cells can be recruited to suppress anti-tumor immunity. TRAIL induces cytokine production via NFkB2, promoting neutrophil chemotaxis and neutrophil-mediated immune suppression in triple negative breast cancer cells. Epstein-Barr virus induces aberrant B cell migration via FAK-dependent chemotaxis, contributing to EBV-associated malignancies.
Inflammatory and metabolic diseases
Dysregulated chemotaxis contributes to chronic inflammation and metabolic disorders. In obesity, mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue, linking chemotaxis to adipose remodeling. CCRL2 regulation of leukocyte migration is critical for resolving inflammation, and its dysfunction can lead to persistent immune cell infiltration.
Primary atopic disorders
Primary atopic disorders (PAD) can result from mutations in genes involved in chemotaxis and immune regulation. Rapid identification of PAD by clinical landmark-guided genomic sequencing has revealed variants in chemotaxis-related genes, highlighting the importance of negative chemotaxis in allergic diseases.
Bacterial infections and dormancy
Bacterial pathogens use negative chemotaxis to escape hostile environments and establish infections. Gram-negative cells exiting dormancy show defined temporal expression patterns that include chemotaxis genes. Myxococcus xanthus development is influenced by beta-lactamase induction, which intersects with chemotaxis pathways.
From induction of negative chemotaxis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CCRL2 regulate leukocyte migration in vivo? | CCRL2 knockout mouse |
| How does TRAIL induce neutrophil chemotaxis in cancer? | TRAIL knockout cancer cell lines; co-culture with neutrophils |
| What is the role of FAK in EBV-induced B cell migration? | FAK knockout B cell lines; EBV infection |
| Can CXCR2 expression be modulated by mirabegron? | CXCR2 overexpression in adipocytes; mirabegron treatment |
| How do PTS components regulate bacterial chemotaxis? | PTS point mutants in E. coli; chemotaxis assays |
| What genes are required for Myxococcus xanthus development? | Beta-lactamase knockout in M. xanthus; developmental assays |
How to Study the induction of negative chemotaxis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Transwell migration assay | Directed cell movement across a membrane | Quantifying chemotaxis induction in leukocytes |
| Live-cell imaging | Real-time cell movement and morphology | Visualizing FAK-dependent migration |
| RNA-seq | Global gene expression changes | Identifying chemotaxis-related genes during dormancy exit |
| CRISPR knockout screening | Loss-of-function effects on chemotaxis | Discovering novel regulators of negative chemotaxis |
| Phosphoproteomics | Signaling pathway activation | Mapping FAK and NFkB2 pathways [2,3] |
| Bacterial chemotaxis assay | Flagellar rotation and swimming behavior | Studying PTS-mediated chemotaxis |
| Flow cytometry | Cell surface receptor expression | Measuring CXCR2 levels after mirabegron treatment |
| Genomic sequencing | Identification of variants in chemotaxis genes | Diagnosing primary atopic disorders |
Chemotaxis assays
Chemotaxis assays, such as transwell migration and under-agarose assays, are used to measure the directed movement of cells in response to chemical gradients. These assays can quantify the induction of negative chemotaxis by tracking cell movement away from a chemoattractant source [6,8].
Live-cell imaging
Live-cell imaging with fluorescently labeled cells allows real-time visualization of chemotaxis induction and cytoskeletal dynamics. This method is particularly useful for studying FAK-dependent migration in B cells.
Transcriptomics and RNA-seq
RNA sequencing can identify genes whose expression changes during the induction of negative chemotaxis. For example, temporal expression patterns in gram-negative bacteria exiting dormancy were defined using transcriptomics.
CRISPR screening
Genome-wide CRISPR screens can identify genes essential for chemotaxis induction. This approach has been used to discover regulators of leukocyte migration and can be applied to cancer and immune cells [1,6].
How CRISPR Can Be Used to Study GO:0050929 induction of negative chemotaxis
Knockout
CRISPR knockout of genes such as CCRL2, CXCR2, or FAK can abolish the induction of negative chemotaxis, allowing researchers to determine their essential roles. For example, FAK knockout in B cells impairs EBV-induced migration.
Point Mutation
Introducing point mutations in chemokine receptors or signaling molecules can dissect specific residues required for chemotaxis induction. This approach is useful for studying receptor-ligand interactions and phosphorylation sites.
Knock-in
Knock-in of fluorescent tags or reporter genes into chemotaxis-related loci enables real-time tracking of protein localization and expression during migration. Tagged CCRL2 can reveal its trafficking in leukocytes.
Overexpression
Overexpression of chemotaxis genes, such as CXCR2 or TRAIL, can enhance or induce negative chemotaxis in cell lines, providing gain-of-function models to study signaling and therapeutic targeting [3,8].
How EDITGENE Supports induction of negative chemotaxis Research
Researchers studying induction of negative chemotaxis-related genes often need to determine whether a candidate gene is causally involved in initiating directed cell movement away from chemical gradients. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such functional studies.
Contact EDITGENE today to design your custom CRISPR model for induction of negative chemotaxis research.
Frequently Asked Questions About induction of negative chemotaxis
What is induction of negative chemotaxis?
Induction of negative chemotaxis (GO:0050929) is the process that initiates directed movement of a cell or organism away from a higher concentration of a chemical, toward a lower concentration [1,6].
What genes are involved in induction of negative chemotaxis?
Key genes include CCRL2, CXCR2, FAK, NFkB2, and TRAIL, as well as bacterial PTS components and beta-lactamase [2,3,5,6,7,8].
How is negative chemotaxis induced in immune cells?
Chemokine receptors such as CCRL2 and CXCR2 bind ligands, activating FAK and NFkB2 signaling to trigger cytoskeletal changes and migration away from the chemical source [2,3,6].
What diseases are associated with defective negative chemotaxis?
Defective negative chemotaxis is linked to cancer metastasis, chronic inflammation, obesity, primary atopic disorders, and bacterial infections [1,2,3,8].
What methods are used to study induction of negative chemotaxis?
Common methods include transwell migration assays, live-cell imaging, RNA-seq, CRISPR screens, and phosphoproteomics [1,2,4,6].
Can CRISPR be used to study negative chemotaxis?
Yes, CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect gene function in negative chemotaxis [1,2,6].
What is the role of CCRL2 in chemotaxis?
CCRL2 is an atypical chemokine receptor that regulates leukocyte migration by scavenging chemokines and modulating receptor signaling.
How does Epstein-Barr virus affect chemotaxis?
EBV induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways, contributing to viral pathogenesis.
What is the link between TRAIL and neutrophil chemotaxis?
TRAIL induces cytokine production via NFkB2, promoting neutrophil chemotaxis and immune suppression in triple negative breast cancer.
How does mirabegron affect chemotaxis?
Mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue in obesity, thereby modulating chemotaxis.
Conclusion
Induction of negative chemotaxis (GO:0050929) is a fundamental biological process that initiates directed cell movement away from chemical gradients. It is critical for immune cell trafficking, cancer progression, bacterial behavior, and metabolic regulation. Key genes such as CCRL2, CXCR2, FAK, and TRAIL have been identified as central players, and CRISPR-based models are invaluable for dissecting their functions. Understanding the molecular mechanisms of negative chemotaxis induction offers promising avenues for therapeutic intervention in inflammatory diseases, cancer, and infections.
References
- 1. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 2. Delecluse S et al.. 2025. Epstein-Barr virus induces aberrant B cell migration and diapedesis via FAK-dependent chemotaxis pathways.. Nat Commun 16(1):4581 PMID: 40389409
- 3. Kundu M et al.. 2025. TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.. Cancer Lett 620:217692 PMID: 40187604
- 4. Ashok N et al.. 2020. Evidence of defined temporal expression patterns that lead a gram-negative cell out of dormancy.. PLoS Genet 16(3):e1008660 PMID: 32203501
- 5. Postma PW et al.. 1993. Phosphoenolpyruvate:carbohydrate phosphotransferase systems of bacteria.. Microbiol Rev 57(3):543-94 PMID: 8246840
- 6. Schioppa T et al.. 2020. Molecular Basis for CCRL2 Regulation of Leukocyte Migration.. Front Cell Dev Biol 8:615031 PMID: 33363177
- 7. O'Connor KA et al.. 1999. Induction of beta-lactamase influences the course of development in Myxococcus xanthus.. J Bacteriol 181(20):6319-31 PMID: 10515921
- 8. Finlin BS et al.. 2025. Mirabegron treatment reduces myofibroblasts and CXCR2 expression in adipose tissue in obesity.. Mol Med 31(1):313 PMID: 41087927
